Effect of Cannabis on E-Cigarette Use Behavior

Description

The purpose of this study is to determine the impact of tetrahydrocannabinol (THC) administration on motivational, subjective, and physiological effects of electronic cigarettes. The study's goals are to test demand for e-cigarettes, tobacco craving, affect, heart rate, blood pressure, expired breath carbon monoxide, and cognitive performance. Researchers will compare multiple doses of THC and a placebo in participants who smoke e-cigarettes and either smoke or vape THC in the laboratory.

Conditions

Cannabis Use, Tobacco Use, Electronic Cigarette Use

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to determine the impact of tetrahydrocannabinol (THC) administration on motivational, subjective, and physiological effects of electronic cigarettes. The study's goals are to test demand for e-cigarettes, tobacco craving, affect, heart rate, blood pressure, expired breath carbon monoxide, and cognitive performance. Researchers will compare multiple doses of THC and a placebo in participants who smoke e-cigarettes and either smoke or vape THC in the laboratory.

Effect of Cannabinoids on Tobacco Product Demand and Pharmacodynamics: Electronic Cigarette Use

Effect of Cannabis on E-Cigarette Use Behavior

Condition
Cannabis Use
Intervention / Treatment

-

Contacts and Locations

Baltimore

Johns Hopkins University Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States, 21224

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Healthy non-treatment seeking adults aged 21 or older
  • 2. Report daily use of e-cigarettes
  • 3. Biological confirmation of e-cigarette use: have an expired carbon monoxide (CO) level of less than 6 ppm and a positive urine cotinine test at screening
  • 4. Report current use of cannabis (at least 1 occasion per week)
  • 5. Have experience with the inhalation route of administration for cannabis
  • 6. Biological confirmation of cannabis use: have a positive urinary THC drug test at screening.
  • 7. For women of children bearing potential and men with female partners of child-bearing potential, must be willing to use an effective form of contraception during the study.
  • 1. Report current intention to reduce or quit cannabis or tobacco use within the next 30 days
  • 2. Meet Diagnostic and Statistical Manual (DSM-5) criteria for a substance use disorder other than alcohol, cannabis, or nicotine
  • 3. Test positive for illicit drugs other than cannabis and tobacco
  • 4. Positive breath alcohol test at study admission
  • 5. Have a current physical or mental illness judged by the study team to negatively impact participant safety or scientific integrity
  • 6. Have a lifetime history of suicidal behavior (i.e. past suicide attempt), or current suicidal behavior or ideation as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)
  • 7. Are currently pregnant, planning to become pregnant in the next three months or are currently breastfeeding
  • 8. Have a history of clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina)
  • 9. Are currently enrolled in another clinical trial or have received any drug as part of a research study within 30 days of study participation.

Ages Eligible for Study

21 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Johns Hopkins University,

Dustin Lee, PhD, PRINCIPAL_INVESTIGATOR, Johns Hopkins School of Medicine

Study Record Dates

2029-10-01